Equities
  • Price (EUR)2.11
  • Today's Change0.004 / 0.19%
  • Shares traded0.00
  • 1 Year change4.15%
  • Beta1.1762
Data delayed at least 15 minutes, as of Nov 26 2020 15:30 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be biotechs, pharmas, medtech companies, universities and inventors.

  • Revenue in USD (TTM)51.81m
  • Net income in USD-85.65m
  • Incorporated1986
  • Employees75.00
  • Location
    PDL BioPharma Inc932 Southwood BlvdINCLINE VILLAGE 89451United StatesUSA
  • Phone+1 (775) 832-8500
  • Fax+1 (775) 832-8501
  • Websitehttp://www.pdl.com
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.